BCAL Diagnostics Limited (BDX.XA)

0.1150 0.0000 (0.00%) At close: 11:36AM AEST

BCAL Diagnostics Limited

50 Clarence Street
Suite 506 Level 5
Sydney, NSW 2000
Australia
61 2 9078 7671
https://www.bcaldiagnostics.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Jayne Andrea Shaw	Co-Founder & Executive Chairman	180k	N/A	N/A
Mr. Shane Ryan M.B.A.	Chief Executive Officer	467.02k	N/A	N/A
Hon. Ronald Anthony Phillips A.O.	Co-Founder & Non-Executive Director	54.66k	N/A	N/A
Dr. Amani Baterseh Ph.D.	Chief Scientist Officer	235.31k	N/A	N/A
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD	CFO & Company Secretary	N/A	N/A	1953
Sean Kennedy	Director of Corporate Finance	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

Corporate governance

BCAL Diagnostics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.